Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epsi-gam in allergic subjects
NCT02559258Phase 1Terminated
- Sponsor
- Tunitas Therapeutics
- Start
- Aug 2015
- Primary completion
- May 2016
- Modality
- Peptide-Drug Conjugates, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GE2 in cat allergy, dust mite allergy and Bermuda grass allergy (5 cohorts), sponsored by Tunitas Therapeutics. Primary endpoint: Safety and tolerability at Day 57. Started Aug 2015; status: terminated.
02
Drugs
GE2
03
Conditions
cat allergydust mite allergyBermuda grass allergy
Beyond the preview
Go deeper on NCT02559258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02559258.